Early Exposure of Murine Embryonic Stem Cells to Hematopoietic Cytokines Differentially Directs Definitive Erythropoiesis and Cardiomyogenesis in Alginate Hydrogel Three-Dimensional Cultures

Iliana Fauzi, Nicki Panoskaltsis, and Athanasios Mantalaris

HepG2-conditioned medium (CM) facilitates early differentiation of murine embryonic stem cells (mESCs) into hematopoietic cells in two-dimensional cultures through formation of embryoid-like colonies (ELCs), bypassing embryoid body (EB) formation. We now demonstrate that three-dimensional (3D) cultures of alginate-encapsulated mESCs cultured in a rotating wall vessel bioreactor can be differentially driven toward definitive erythropoiesis and cardiomyogenesis in the absence of ELC formation. Three groups were evaluated: mESCs in maintenance medium with leukemia inhibitory factor (LIF, control) and mESCs cultured with HepG2 CM (CM1 and CM2). Control and CM1 groups were cultivated for 8 days in early differentiation medium with murine stem cell factor (mSCF) followed by 10 days in hematopoietic differentiation medium (HDM) containing human erythropoietin, m-interleukin (mIL)-3, and mSCF. CM2 cells were cultured for 18 days in HDM, bypassing early differentiation. In CM1, a fivefold expansion of hematopoietic colonies was observed at day 14, with enhancement of erythroid progenitors, hematopoietic genes (Gata-2 and SCL), erythroid genes (EKLF and β-major globin), and proteins (Gata-1 and β-globin), although ε-globin was not expressed. In contrast, CM2 primarily produced beating colonies in standard hematopoietic colony assay and expressed early cardiomyogenic markers, anti-sarcomeric α-actinin and Gata-4. In conclusion, a scalable, automatable, integrated, 3D bioprocess for the differentiation of mESC toward definitive erythroblasts has been established. Interestingly, cardiomyogenesis was also directed in a specific protocol with HepG2 CM and hematopoietic cytokines making this platform a useful tool for the study of erythroid and cardiomyogenic development.

Introduction

Hematopoiesis in the early mouse embryo has been recapitulated by in vitro differentiation culture of human and murine embryonic stem cells (mESCs) by which mesodermal cells commit to the hematopoietic lineage before giving rise to other blood cells [1–7]. During embryogenesis, hematopoietic cells originate from the lateral plate mesoderm in an ordered program of development occurring in conjunction with cells of the cardiovascular system and share a common precursor, the hemangioblast [8–11]. The study of the hemangioblast, hemogenic endothelial cells and endothelial-to-hematopoietic transition [12–14] is critical to the understanding of related pathologies and for the development of a robust and reliable in vitro method of ESC differentiation toward cells, such as red blood cells (RBCs), which may be used in future clinical translational protocols [15–17].

Current protocols for in vitro production of RBCs from ESCs are fragmented and involve multiple (three) stages: (1) maintenance/expansion of undifferentiated ESCs, (2) spontaneous differentiation through formation of embryoid bodies (EBs) incorporating all three germ layers, and (3) dissociation of EBs with re-plating for terminal differentiation to desired lineages [16,18]. Ideal conditions for such cultures are not fully identified but result in sub-optimal control of differentiation and heterogeneity [19,20]. To date, the most efficient protocols for generation of oxygen-transporting, enucleated RBCs from ESCs require co-culture with feeder cells and a complex, fragmented multi-step process requiring at least 1 month of culture, which renders such protocols impractical and difficult to scale up [16,17]. EB cavitation during the process also results in cell loss and further reduces the yield and quality of cellular products [21,22]. In contrast to these two-dimensional (2D) cultures, three-
dimensional (3D) systems can produce a controllable and scalable high cell-density culture of ESCs with a reduction in shear stress to cells that still maintain the capacity to terminally differentiate [23–26]. However, these methodologies for directed differentiation involved EB formation [25,26] and generated heterogeneous cell types [20] that were unsuitable for potential therapeutic applications. Furthermore, 3D cultures with increased cell density face mass transport limitations in static conditions resulting in an inhomogeneous environment, and a decrease in total cell output [27]. To overcome these limitations, we and others use bioreactors to accommodate dynamic ESC culture conditions and enable large-scale production [26,28–32].

Our previous work demonstrated that HepG2 conditioned medium (CM), obtained from cultures of the human hepatocarcinoma cell-line HepG2, enhanced mesoderm formation from mESCs [33,34] in the absence of EB formation [31,35,36], and facilitated early differentiation of hematopoietic cells in standard, monolayer 2D cultures [36]. We have recently developed an integrated bioprocess for the expansion and differentiation of mESCs using encapsulation and a rotating wall vessel (RWV) bioreactor system in a single-step process that does not require formation of EBs or the disruption of cell aggregates, and results in 3D tissue formation [31,32]. We now extend these studies and describe an efficient, integrated bioprocess for in vitro erythropoiesis from mESCs that (1) facilitates 3D culture through encapsulation of undifferentiated mESCs in alginate hydrogels, (2) uses CM to efficiently stimulate mesoderm formation, (3) bypasses EB formation, and (4) involves culture in an RWV bioreactor that requires minimal handling (cell passaging is not required) and which is scalable and automatable in a cost-effective manner. Our results demonstrate a viable platform for the convenient study and application of definitive erythropoietic cells in standard, monolayer 2D cultures [36] and enabled early differentiation of hematopoietic lineage from mESCs [35,36], followed by 8 days in early differentiation medium (HDM) containing Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen), 15% FBS (Gibco), 2 mM L-glutamine (Gibco), 0.45 mM α-1,2-monohydroxy-alginic acid (Sigma), 10 mg/mL bovine insulin, 5.5 mg/mL human transferrin, 5 mg/mL sodium selenite (ITS liquid media supplement; Sigma), and supplemented with 40 ng/mL mSCF (R&D Systems). Thereafter, the cells were cultured for 10 days in hematopoietic differentiation medium (HDM) directed toward erythropoiesis consisting of EDM with mSCF supplemented with 10 ng/mL mIL3 and 3 U/mL human erythropoietin (hEPO) (all from R&D Systems; modified from previous studies [36,37]). The first experimental group (CM1) consisted of undifferentiated mESCs encapsulated and cultured for 3 days in a 1:1 (v/v) mixture of HepG2 CM and standard maintenance medium (BM) [33,36], followed by 8 days of culture in EDM with mSCF and 10 days in HDM, described earlier. The second experimental group (CM2) was similarly cultured for 3 days in a 1:1 (v/v) mixture of HepG2 CM and BM, followed by direct culture in HDM (bypassing the early

### Materials and Methods

#### Cell cultures

**Cell lines and encapsulation of mESCs.** Undifferentiated mESCs (E14/TG2-a cell line; ATCC; \( P < 20 \)) were cultured according to standard mESC culture protocol [31,33] before the encapsulation process. Maintenance of HepG2 cells (ATCC, HB-8605; \( P < 80 \)) and preparation of CM was done as previously described [33]. Undifferentiated mESCs (10×10⁶ cells) were suspended in 4 mL sterile-filtered (0.2 μm) alginateic acid (v/v) and 0.1% (v/v) gelatin solution [both from Sigma-Aldrich; diluted in phosphate-buffered saline (PBS), pH 7.4] [31]. The cell-gel solution was passed through a peristaltic pump (Model P-1; Amersham Biosciences) and dropped using a 25-gauge needle into sterile alginate gelation solution (100 mM CaCl₂; Sigma) with 10 mM HEPES (Sigma) and 0.01% (v/v) Tween (Sigma) at pH 7.4 with magnetic stirring. The alginate-encapsulated cells remained in gently stirred CaCl₂ solution for 6–10 min, and were then washed twice with PBS.

**Bioprocessing of 3D mESCs.** A total number of \( 1 \times 10⁷ \) undifferentiated mESCs were encapsulated in alginate hydrogel to produce 500 cell beads (approximately \( 2 \times 10⁴ \) cells per bead; bead diameter = 2.5 mm), and the beads were cultured in a 50 mL RWV HARV bioreactor (Synthecon), with daily replenishment of medium. Three groups were assessed simultaneously in RWV culture (Table 1). The control group consisted of undifferentiated mESCs encapsulated and cultured for 3 days in standard maintenance medium with leukemia inhibitory factor (LIF) as previously described [31,33], followed by 8 days in early differentiation medium (EDM) containing Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen), 15% FBS (Gibco), 2 mM L-glutamine (Gibco), 0.45 mM α-1,2-monohydroxy-alginic acid (Sigma), 10 mg/mL bovine insulin, 5.5 mg/mL human transferrin, 5 mg/mL sodium selenite (ITS liquid media supplement; Sigma), and supplemented with 40 ng/mL mSCF (R&D Systems). Thereafter, the cells were cultured for 10 days in hematopoietic differentiation medium (HDM) directed toward erythropoiesis consisting of EDM with mSCF supplemented with 10 ng/mL mIL3 and 3 U/mL human erythropoietin (hEPO) (all from R&D Systems; modified from previous studies [36,37]). The first experimental group (CM1) consisted of undifferentiated mESCs encapsulated and cultured for 3 days in a 1:1 (v/v) mixture of HepG2 CM and standard maintenance basal medium (BM) [33,36], followed by 8 days of culture in EDM with mSCF and 10 days in HDM, described earlier. The second experimental group (CM2) was similarly cultured for 3 days in a 1:1 (v/v) mixture of HepG2 CM and BM, followed by direct culture in HDM (bypassing the early differentiation medium; LIF, leukemia inhibitory factor; mESC, murine embryonic stem cell; mSCF, murine stem cell factor.

### Table 1. Experimental Plan

<table>
<thead>
<tr>
<th>Experimental groups</th>
<th>2D Maintenance</th>
<th>3D Early differentiation</th>
<th>3D Late differentiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>BM+LIF (3 days)</td>
<td>EDM+mSCF (8 days)</td>
<td>HDM (10 days)</td>
</tr>
<tr>
<td>CM1</td>
<td>BM+LIF (3 days)</td>
<td>EDM+mSCF (8 days)</td>
<td>HDM (10 days)</td>
</tr>
<tr>
<td>CM2</td>
<td>BM+LIF (3 days)</td>
<td>EDM+mSCF (8 days)</td>
<td>HDM (18 days)</td>
</tr>
</tbody>
</table>

Three mESCs groups were assessed: (1) control (3 days’ standard maintenance medium and then 8 days’ early differentiation medium), (2) CM1 (3 days’ CM and then 8 days’ early differentiation medium), and (3) CM2 (3 days’ CM, bypassing early differentiation). All underwent hematopoietic differentiation with hEPO, mIL3-3, and mSCF to 21 culture days.

2D, two-dimensional; 3D, three-dimensional; BM, basal medium; EDM, early differentiation medium; HDM, hematopoietic differentiation medium; LIF, leukemia inhibitory factor; mESC, murine embryonic stem cell; mSCF, murine stem cell factor.
differentiation step) for 18 days (Table 1). In preliminary experiments, 3D-encapsulated mESCs exposed only to CM throughout the 21 day RWV culture period (with LIF added in the first 3 days only) was also evaluated as an additional control group.

**Live and dead assay**

Viability of cells within the alginate hydrogels was observed using two-colour fluorescent Live/Dead Assay (Molecular Probes) as per manufacturer’s instructions. Briefly, 4 mM EthD-1 and 2 mM calcine AM solution was prepared in PBS and added to the alginate-encapsulated cells, with 30 min incubation at room temperature in the dark. The cell-hydrogel beads were washed twice with PBS and visualized under an Olympus BX51 microscope (Olympus). Images were captured using the F-view unit (Soft Imaging System GmbH) with U-MNIBA3 (FITC) and U-MWY2 (Texas Red) filters. Image staining intensity was quantified with Image J analysis software [38] (NIH). Images were not manipulated.

**Hematopoietic CFU assay**

After 21 days culture in the RWV, a cell suspension containing 2 × 10^5 cells/mL was collected by dissolving alginate cell hydrogels in a sterile depolymerization buffer as outlined earlier. The cells were then plated in standard methylcellulose hematopoietic colony-forming medium containing IMDM supplemented with 15% FBS, 2 mM l-glutamine, 150 μM MTG, 1% BIT (1% BSA, 10 μg/mL Insulin, and 200 μg/mL Transferrin; Stem Cell Technologies), 150 ng/mL mSCF, 30 ng/mL mIL-3, 30 ng/mL hIL-6, 3 U/mL hePO (all from R&D), and 1% basic methylcellulose medium (Stem Cell Technologies). Cell suspensions were placed on low-adherence 35 mm Petri dishes (VWR International Ltd.) and cultivated for an additional 14 days at 37°C with 5% CO₂ in a humidified incubator. Resultant colonies were scored and counted using standard criteria for burst-forming unit-erythroid (BFU-E), CFU-erythroid (CFU-E), CFU-granulocyte, macrophage (CFU-GM), and CFU-granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM). Colonies were individually plucked for further analysis.

**Wright–Giemsa staining**

Cytospins (1 × 10^6 cells/mL) from CFUs of control and CM1 groups were prepared, stained with Wright–Giemsa (Sigma; 10 s), and subsequently washed in deionized (DI) water for 2 min. Cells were visualized with an Olympus BX51 microscope; images were captured using the DP50 camera (Olympus) and not manipulated after capture.

**Reverse transcriptase-polymerase chain reaction**

Cell pellets from de-capsulated beads and CFUs were stored at −80°C before RNA extraction using the total RNA isolation kit (Qiagen Ltd.). Single-stranded cDNA synthesis was performed with 1 mg total RNA using a random primer and AMV reverse transcriptase with an RNase inhibitor (Promega). The subsequent polymerase chain reaction was performed as previously described [36] with primers detailed in Table 2.

**Western blot analysis**

Total protein extracted from CFUs of control mESCs, CM1, and CM2 groups was quantified using the BCA™ Assay Kit (Thermo Fisher Scientific). BSA (Sigma) was used as a known protein standard. Protein blotting reactions were performed as previously described [36]. Primary antibodies used were rabbit anti-mGata-1 polyclonal (1:2,000), rabbit anti-m-α-globin polyclonal (1:2,000), chicken anti-m-β-major globin polyclonal (1:2,000), and rabbit anti-mGAPDH polyclonal (1:20,000). Secondary antibodies, anti-rabbit, and anti-chicken polyclonal IgG were conjugated to Horseradish...
### Results

**Alginate-encapsulated mESCs exposed to HepG2 CM and hematopoietic cytokines have enhanced viability and proliferation yet similar metabolism**

Viability of encapsulated mESCs within the alginate hydrogels was determined using a two-color fluorescence live/dead assay that measures intracellular esterase activity and plasma membrane integrity. At day 3, encapsulated undifferentiated mESCs were observed in small cell aggregates of 20 μm (Fig. 1). However, during early differentiation and terminal hematopoietic differentiation, more and larger viable cell aggregates were formed after 20 days of culture with the largest observed in CM2 (200 μm) > CM1 > Control (100 μm), indicating that nutrient mass transport limitations were not experienced within the hydrogels. Cells of the CM2 group had the highest viability (>95%), 2.3-fold higher than that of the control group (1 x; CM1 1.5-fold). A higher proliferation rate was observed for CM2 and CM1 when compared with that of the control from 6 days until 15 days of culture before reaching a plateau phase; CM2 had the highest number of cells at the end of culture with an approximately 15-fold expansion (Fig. 1B). Correlating with these higher cell densities later in the culture, the pH level initially was 7.5 and gradually declined to 7.3 (Fig. 2). In contrast, nutrient consumption kinetics showed a significant reduction from 23 to 0 mM and from 4.5 to 0.15 mM, for glucose and glutamine, respectively, even at day 3 of culture with a commensurate accumulation of lactate and ammonia. The kinetics was indicative of the high metabolic activity of alginate-encapsulated cells within the RWV bioreactor cultures. Interestingly, despite these drastic changes in nutrients and metabolites, the viability and proliferation of cells in culture (Fig. 1) was adequately supported by medium exchange every 3 days. Although the CM2 group had a similar proliferation profile to that of CM1 (both were higher than the control), there was a significant difference in pH level, glutamine consumption, lactate and ammonia production between CM2 and both CM1 and control on day 11 (when mESCs and CM1 were exposed to HDM) and at the end of the culture, indicative of the lower metabolic requirements of maturing cells within CM2 at these time points. In summary, encapsulation and culture in a RWV bioreactor facilitated high viable cell densities at 21 days, with a total output of 1.5 x 10⁶ cells total in 500 hydrogel beads (15-fold expansion), minimal mass-transport effects, and the potential for control and optimization of metabolic parameters.

**Directed hematopoietic differentiation is dependent on early exposure to mSCF, whereas cardiomyogenic differentiation occurs with early exposure to mSCF, mIL-3, and hEPO**

Gene expression analysis was performed on the decapsulated cells at days 1, 4, 9, and 15 of culture (Fig. 3A). Expression of the pluripotency gene, Oct-4, was maintained...
in the control group until at least day 4, indicating that at least some pluripotent capacity was retained, which was in contrast to the CM1 and CM2 groups exposed to the HepG2 CM. During differentiation, the mesoderm genes, Brachyury (Brac-T) and Flk-1, were clearly expressed early at day 4 and 9 in the CM1 and CM2 groups with delayed expression at day 15 in the control group, consistent with the known effects of HepG2 CM in enhancing mesoderm formation [33,36]. Expression of the early hematopoietic and erythroid genes Gata-2, SCL, and EKLF was earlier in CM1 and CM2 compared with that of the control, with the highest consistent expression in CM1. Interestingly, although Gata-4 increased from day 4 in all conditions, a distinct high intensity band was observed in CM2 at day 15 of culture in conjunction with maintained expression of Flk-1 and coincident with a fall in all hematopoiesis-specific genes, in particular Gata-2, which peaked at day 9; this expression pattern was suggestive of cardiomyogenic gene upregulation under the influence of hematopoietic cytokines within the differentiation medium. The enhanced hematopoietic maturation in CM1 by day 15 was supported by the increased expression of erythroid antigens CD71 (2.6-fold higher) and TER119 (1.8-fold higher) compared with that of CM2 (1.4-fold CD71, 1.1-fold TER119) and control (1×) groups (Fig. 3B). These results suggested that the conditions of CM1 were most conducive to directed erythroid differentiation and that of CM2, which bypassed the early differentiation stage, expressed a more prominent cardiomyogenic signature on direct exposure to hematopoietic cytokines.

**Early exposure to mSCF favored definitive erythroid colony development, whereas early exposure to mSCF, mIL-3, and hEPO resulted in cardiomyogenic beating colonies (“CFU-Beat”)**

At the end of the 21-day culture period, de-capsulated terminally differentiated cells were re-plated in methylcellulose with a hematopoietic cytokine cocktail in CFU assay to assess functionality. The control group formed mostly myeloid progenitors, identified by formation of CFU-GM colonies, confirmed by Wright–Giemsa staining showing macrophages (Fig. 4A). In contrast, a higher number of hematopoietic progenitor colonies, consisting mostly of erythroid colonies, BFU-E, and CFU-E, was achieved from the CM1 group after 14-day methylcellulose culture (Fig. 4B; \( P \leq 0.01 \)) with a fivefold enhancement compared with that of control and CM2 groups. Macrophages with nucleated erythrocytes (nE) were observed in cytospins of CM1, indicative of erythroid islands needed to support BFU-Es [39] (Fig. 4A). Interestingly, despite the early exposure to mSCF, mIL-3, and hEPO and the hematopoietic cytokine cocktail inherent in standard methylcellulose CFU assay, beating colonies (“CFU-Beat”) dominated the CFU assay of CM2 (Supplementary
3D mESC Culture for Blood and Heart Cell Production

Myeloid lineage. These results indicated that, in this 3D system, early exposure of mESCs to mSCF directed definitive differentiation program was committed toward hematopoietic-erythroid genes or proteins, confirming that the hematopoietic hematopoietic markers, CFU assay. CFUs from the control group expressed early Beasts on exposure to standard hematopoietic cytokines of the dominant cardiomyogenic differentiation pathway in CFU-observed from colonies collected from CM2, indicative of the gene expression as well as protein expression of the early erythroid marker Gata-1 and further gene (Fig. 4C) and protein analysis (Fig. 4D) of CFUs cardiomyogenic differentiation in the CFU-Beat (Fig. 4A). The RWV bioreactor did not form CFU-Beats (data not shown).

Video S1: 22 beats per minute observed; Supplementary Data are available online at www.liebertpub.com/scd). CFU-Beats were only observed in the CM2 group, with a small population of mixed hematopoietic colonies formed (16% of total). Encapsulated mESCs exposed only to HepG2 CM for 21 days in the RWV bioreactor did not form CFU-Beats (data not shown). Fluorescence staining for anti-sarcomeric α-actinin confirmed cardiomyogenic differentiation in the CFU-Beat (Fig. 4A). Further gene (Fig. 4C) and protein analysis (Fig. 4D) of CFUs from CM1 showed higher Gata-2, SCL, and β-major globin gene expression as well as protein expression of the early erythroid marker Gata-1 and β-globin with lack of ζ-globin, confirming that hematopoietic differentiation toward the definitive erythroid lineage was successfully achieved. In contrast, expression of Gata-4 and α-MHC genes was only observed from colonies collected from CM2, indicative of the dominant cardiomyogenic differentiation pathway in CFU-Beats on exposure to standard hematopoietic cytokines of the CFU assay. CFUs from the control group expressed early hematopoietic markers, Gata-2 and SCL, without expression of erythroid genes or proteins, confirming that the hematopoietic differentiation program was committed toward hematopoietic-myeloid lineage. These results indicated that, in this 3D system, early exposure of mESCs to mSCF directed definitive erythroid maturation, whereas early exposure to mSCF, mIL-3, and hEPO resulted in functional cardiomyogenic differentiation preferentially even on direct exposure to hematopoietic cytokines in standard hematopoietic CFU assay.

Discussion

We have described an integrated single-step 3D bioprocess for the efficient and directed generation of definitive erythroid and cardiomyogenic cells from alginate-encapsulated mESCs in the absence of standard EB or embryoid-like colony-formation. The formation of erythroid progenitors and beating colonies based on early exposure to hematopoietic cytokines was most interesting and indicated a differential effect of the hematopoietic cytokines IL-3 and EPO (in combination with SCF) toward cardiomyogenesis in the absence of specific cardiomyogenic factors, whereas SCF alone was most conducive to erythropoiesis from the mesodermal stage of development. This 3D system, more reflective of in vivo events than 2D systems, will be instructive as an in vitro model of erythropoiesis, in the study of the hemangioblast and in the competitive hematopoietic-cardiomyogenic developmental pathways. It could also provide a viable, robust, automatable, and scalable platform for large-scale production of stem cell-derived RBCs, and other ESC-derived cellular products, in translational protocols.

The ability to monitor and modulate pH, glucose/glutamine consumption, lactate and ammonia production is instrumental in controlling and standardizing cell growth and differentiation outputs [40]. Although a drastic decline in glucose/glutamine concentrations and an accumulation of metabolic by-products was observed, the pH level (7.3) was acceptable [41] during the culture period and indicated that the feeding schedule was practical. Indeed, low-glucose conditions may be more suitable for ESC differentiation and growth [42–45], and are conducive to myeloid and erythroid growth [46] with glutamine-deficient conditions inducing erythroid differentiation [47,48]. Although glucose uptake increases during cardiomyogenesis [49], low glucose conditions can also support cardiomyogenic differentiation [50]. The effect of pH on cardiomyogenesis is not elucidated, but lower pH levels may induce formation of the three germ layers during ESC culture [51], and erythroid differentiation accelerates with increasing extracellular pH (range 7.1–7.6) [52]. The day 11 and 21 time points of the culture indicated altered metabolism of cells in the CM2 condition, leading to cardiomyogenesis and a future study of metabolic pathways in this model system may, therefore, be informative. The degree to which these parameters affect speed, type, quality, and homogeneity of cell differentiation, especially in 3D tissue culture, needs to be explored.

Early exposure of encapsulated mESCs to SCF in CM1 followed by continuous SCF and addition of EPO and IL-3 directed definitive erythropoiesis and is consistent with what is already known about the actions of these cytokines on hematopoietic stem and progenitor cells and erythroid development. SCF increases cell survival and proliferation of early erythroid progenitors and precursors toward CFU-E, and at the proerythroblast stage [53]. At later maturational stages, its main role is to prevent apoptosis and induce proliferation [54]. In synergy with EPO and SCF, more primitive erythroid progenitors require IL-3 to survive and proliferate in vitro [55]. EPO dramatically increases the

FIG. 4. Clonogenic capacity. (A)(i) CFU morphology (beating area in black circle). (ii&iii) Wright–Giemsa (Mac = macrophages; NE = nucleated erythrocytes) and immunostaining of plucked colonies [(ii) anti-sarcomeric α-actinin-FITC, (iii) DAPI, (iv) composite image]. Negative control insets. Magnification: 20×. Scale: 200 μm. (B) Summary of CFUs (mean cell number±SD, n=3; **P<0.01). (C) CFU gene expression. (D) Western blot of CFUs. (Negative controls = no antibody/cDNA/protein loaded).
number of CFU-E and erythroid precursors up to the stage of basophilic erythroblasts, mainly by preventing apoptosis [56]. The observation that early exposure to all three cytokines was most conducive to cardiomyocyte development rather than erythropoiesis may provide further insights into morphogens and patterning in response to these cytokines during embryogenesis [57] as well as the impact they have on combined pathological states of cardiac and bone marrow tissues in the adult.

One of the first key events that precedes the emergence of hematopoietic cells in in vitro studies of mESCs is the expression of the early mesoderm marker, Brac-T, and the coincident appearance of vascular endothelial growth factor (VEGF)-independent cells which form transitional mesoderm colonies of Brac-T+Flk1+ cells [58], Flk-1 (VEGFR2)-positive cells from the primitive streak in early embryogenesis represent one of the earliest mesoderm precursors that are capable of forming cardiac [9], endothelial, and primitive erythroid cells [59]. The next stage is a Brac-T+Flk1+ VEGF-responsive blast (BL)-colony forming cell (CFC) that forms colonies of Brac-T+Flk1+SCL+ cells containing the hemangioblast, generating both endothelial and hematopoietic (either primitive and/or definitive) progeny [1,3]. Our current findings of Brac-T and Flk-1 upregulation, with variable SCL expression, in CM1 and CM2 from day 9 to 15 suggests hemangioblast development in the 3D culture [60]. The spontaneous formation of CFU-Beats after early and continued exposure to hematopoietic cytokines and without further adaptation, apart from standard hematopoietic methylcellulose CFU assay, was unexpected and suggested that cardioprogenitor commitment had occurred in 3D RWV by day 21 in CM2. Previously described cardiovascular-CFCs (CV-CFCs) from day 4.25 Flk-1+ multipotent cardiovascular progenitors were likely generated by a different progenitor population, had cardiac and vascular potential (rather than cardiac and hematopoietic potential as observed here), and occurred only after primary culture in cardio-conductive medium with subsequent secondary liquid culture in order to expand cells and induce contractions [9]. Although it is possible that other factors in HepG2 CM were instrumental in cardiomyogenesis (eg, fibronectin and myosin, heavy chain 3 [61]), there was differential maturation toward erythropoiesis in the absence of IL-3 and EPO, and on exposure of mESCs to CM alone for 21 days in the RWV bioreactor, no CFU-Beats were observed (data not shown), indicating that HepG2 CM mainly played a role in inducing earlier onset mesoderm formation [33,36] rather than having a critical role in the cardiomyogenic developmental pathway. Hematopoietic cytokines affect cardiomyogenic differentiation. In murine embryos, EPO triggers cardiomyocyte proliferation [62]; its receptor is detected by E10.5 until day E14.5 [62,63], and IL-3 can induce endothelial cell formation as well as stimulate and chemo-attract smooth muscle cell proliferation and migration [64]. The formation of mixed lineage hematopoietic cells in the same cultures as CFU-Beats suggests that this may be a good system for future studies on common progenitor cells involved in cardiomyocyte and hematopoietic development in the early embryo, the role of the hemangioblast, the interaction of different cytokines and morphogens at specific timepoints, and the influence of the 3D microenvironment and metabolism.

In summary, we have established a 3D erythropoietic and cardiomyogenic differentiation culture system, bypassing standard EB formation using alginate-encapsulated mESCs cultivated in a RWV bioreactor. This 3D culture platform has demonstrated the importance of SCF, EPO, and IL-3 in erythropoietic and cardiomyogenic maturation and should be a useful tool for the study of these differential and competitive pathways from ESCs in a relevant in vitro system with potential applications in future cellular therapies.

Acknowledgments

This work was funded by the Higher Ministry of Education Malaysia, Universiti Malaysia Terengganu, the Richard Thomas Leukaemia Fund, and the Northwick Park Hospital Leukaemia Research Trust Fund.

Author Disclosure Statement

The authors have no conflicts of interest.

References


Address correspondence to:
Dr. Nicki Panoskaltsis
Department of Hematology
Imperial College London
Northwick Park & St. Mark’s Campus
Harrow, Greater London HA1 3UJ
United Kingdom
E-mail: n.panoskaltsis@imperial.ac.uk

Prof. Athanasios Mantalaris
Biological Systems Engineering Laboratory
Department of Chemical Engineering and Chemical Technology
Imperial College London
South Kensington Campus
London SW7 2AZ
United Kingdom
E-mail: a.mantalaris@imperial.ac.uk

Received for publication February 26, 2014
Accepted after revision June 12, 2014
Prepublished on Liebert Instant Online June 13, 2014